A gender perspective of smoking cessation's health and economic value in Jordanian women: using cost effectiveness model.

IF 2.5 4区 医学 Q3 HEALTH POLICY & SERVICES
Saba Madae'en, Nour Obeidat, Mansour Haddad, Khaled Alrosan, Amjad Z Alrosan, Bayan Shaggour, Rola Madain, Faris Matanes
{"title":"A gender perspective of smoking cessation's health and economic value in Jordanian women: using cost effectiveness model.","authors":"Saba Madae'en, Nour Obeidat, Mansour Haddad, Khaled Alrosan, Amjad Z Alrosan, Bayan Shaggour, Rola Madain, Faris Matanes","doi":"10.1186/s12962-025-00636-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prevalence of smoking among Jordanian females has risen significantly from 10.1% in 2000 to 12.8% in 2022. (Who smokes more, men or women? - Our World in Data), it is imperative to recognize the global scope of this issue, which encompasses both genders. Furthermore, it is vital to discern potential sex-specific variations in the health and economic consequences of smoking cessation. This study aims to investigate the cost-effectiveness of smoking cessation interventions specifically tailored for Jordanian women.</p><p><strong>Methodology: </strong>This study employs a pharmacoeconomic analysis to evaluate the potential cost effectiveness of JFDA-approved smoking cessation medications within the context of Jordanian women. The analysis focused primarily on a comparative assessment of two registered medications in Jordan, varenicline and nicotine replacement therapy (NRT), encompassing nicotine patches and lozenges. These interventions are juxtaposed against a control group representing the current standard practice of medical counseling with no medication use from the Ministry of Health's payer perspective.</p><p><strong>Results: </strong>For a cohort comprising 82,512 Jordanian female smokers seeking to quit, the varenicline regimen yielded a gain of 13,151 life years compared with the 7,265 life years gained with the NRT regimen compared with the no-intervention scenario. The cost per life-year gained was found to be JD 1,689.50 ($ 2383.3) for varenicline and JD 1,892.48. ($2669.63) for NRT. The sensitivity analysis confirmed the robustness of the findings.</p><p><strong>Discussion: </strong>The notably high cost-effectiveness of smoking cessation interventions in females underscores the importance of tailoring approaches to address the needs of female smokers who express an intention to quit. This research highlights the imperative of offering smoking cessation aids to facilitate efforts to quit smoking.</p>","PeriodicalId":47054,"journal":{"name":"Cost Effectiveness and Resource Allocation","volume":"23 1","pages":"41"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333165/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cost Effectiveness and Resource Allocation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12962-025-00636-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The prevalence of smoking among Jordanian females has risen significantly from 10.1% in 2000 to 12.8% in 2022. (Who smokes more, men or women? - Our World in Data), it is imperative to recognize the global scope of this issue, which encompasses both genders. Furthermore, it is vital to discern potential sex-specific variations in the health and economic consequences of smoking cessation. This study aims to investigate the cost-effectiveness of smoking cessation interventions specifically tailored for Jordanian women.

Methodology: This study employs a pharmacoeconomic analysis to evaluate the potential cost effectiveness of JFDA-approved smoking cessation medications within the context of Jordanian women. The analysis focused primarily on a comparative assessment of two registered medications in Jordan, varenicline and nicotine replacement therapy (NRT), encompassing nicotine patches and lozenges. These interventions are juxtaposed against a control group representing the current standard practice of medical counseling with no medication use from the Ministry of Health's payer perspective.

Results: For a cohort comprising 82,512 Jordanian female smokers seeking to quit, the varenicline regimen yielded a gain of 13,151 life years compared with the 7,265 life years gained with the NRT regimen compared with the no-intervention scenario. The cost per life-year gained was found to be JD 1,689.50 ($ 2383.3) for varenicline and JD 1,892.48. ($2669.63) for NRT. The sensitivity analysis confirmed the robustness of the findings.

Discussion: The notably high cost-effectiveness of smoking cessation interventions in females underscores the importance of tailoring approaches to address the needs of female smokers who express an intention to quit. This research highlights the imperative of offering smoking cessation aids to facilitate efforts to quit smoking.

Abstract Image

Abstract Image

从性别角度看约旦妇女戒烟的健康和经济价值:使用成本效益模型。
背景:约旦女性吸烟率从2000年的10.1%显著上升到2022年的12.8%。谁抽烟多,男人还是女人?(我们的数据世界),必须认识到这一问题的全球范围,其中包括男女。此外,至关重要的是要辨别戒烟在健康和经济后果方面的潜在性别差异。本研究旨在调查专门为约旦妇女量身定制的戒烟干预措施的成本效益。方法:本研究采用药物经济学分析来评估jfda批准的戒烟药物在约旦妇女中的潜在成本效益。分析主要集中在约旦两种注册药物的比较评估,即伐尼克兰和尼古丁替代疗法(NRT),包括尼古丁贴片和含片。从卫生部付款人的角度来看,这些干预措施与代表目前不使用药物的医疗咨询标准做法的对照组并置。结果:在一个由82512名约旦女性吸烟者组成的队列中,与NRT方案相比,varenicline方案与无干预方案相比获得了7265年的生命年,而varenicline方案获得了13151年的生命年。varenicline每生命年增加的成本分别为1,689.50迪拉姆(2383.3美元)和1,892.48迪拉姆。(2669.63美元)。敏感性分析证实了研究结果的稳健性。讨论:女性戒烟干预措施的显著高成本效益强调了定制方法的重要性,以满足表达戒烟意愿的女性吸烟者的需求。这项研究强调了提供戒烟辅助以促进戒烟努力的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cost Effectiveness and Resource Allocation
Cost Effectiveness and Resource Allocation HEALTH POLICY & SERVICES-
CiteScore
3.40
自引率
4.30%
发文量
59
审稿时长
34 weeks
期刊介绍: Cost Effectiveness and Resource Allocation is an Open Access, peer-reviewed, online journal that considers manuscripts on all aspects of cost-effectiveness analysis, including conceptual or methodological work, economic evaluations, and policy analysis related to resource allocation at a national or international level. Cost Effectiveness and Resource Allocation is aimed at health economists, health services researchers, and policy-makers with an interest in enhancing the flow and transfer of knowledge relating to efficiency in the health sector. Manuscripts are encouraged from researchers based in low- and middle-income countries, with a view to increasing the international economic evidence base for health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信